NCT04904302 2026-03-20
Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
Clinical Trials
14 trialsNCT02664935 2025-05-21
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
University of Birmingham
Phase 2 Active not recruiting
NCT04925986 2025-04-17
Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC
Yale University
Phase 2 Terminated
NCT03015740 2024-11-19
Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT04123704 2024-08-26
Sitravatinib in Metastatic Breast Cancer
Baylor Breast Care Center
Phase 2 Terminated
NCT02978859 2024-07-18
Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas
Columbia University
Phase 2 Completed
NCT04727996 2024-04-19
BTC-BGB
Seoul National University Hospital
Phase 2 Active not recruiting
NCT05176925 2024-01-29
Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC
Fudan University
Phase 2 Terminated
NCT04734262 2023-11-18
SPARK
Fudan University
Phase 2 Unknown
NCT05228496 2023-09-26
A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT03575598 2023-07-27
SNOW
University Health Network, Toronto
Phase EARLY_PHASE1 Completed
NCT05614453 2023-06-29
ITTACC
Australia New Zealand Gynaecological Oncology Group
Phase 2 Withdrawn
NCT05419817 2023-02-27
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
University of Pittsburgh
Phase 2 Withdrawn
NCT05104801 2021-11-04
Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown